Clinical Trial Update: A Study in Patients With Moderate to Severe Plaque Psoriasis to Evaluate the Efficacy and Safety of ESK-001 [Phase 3]

View source ↗

Summary

Phase 3 study evaluating ESK-001 for moderate to severe plaque psoriasis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plaque Psoriasis

Drugs mentioned

• ESK-001

Snippet

Sponsor: Alumis Inc | Conditions: Plaque Psoriasis | Phase 3 | Status: COMPLETED